ASCO GU 2023 Kidney Cancer

Viewing 1-20 of 24 articles

ASCO GU 2023: The Ever-Changing Pathologic Classification of Renal Cell Carcinoma

ASCO GU 2023: Effect of Treatment of Residual Disease After Immunotherapy-Based Combinations on Complete Response Rate in Metastatic Renal Cell Carcinoma.

ASCO GU 2023: Nivolumab plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced RCC: 3-Year Follow-up from the Phase 3 CheckMate 9ER Trial

ASCO GU 2023: ZIRCON: Results from Phase 3 Study of 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma

ASCO GU 2023: Evaluation of Deep Learning Techniques in RNA Sequencing Data for the Prediction of Response to Immune Checkpoint Inhibitors in Patients with Metastatic Renal Cell Cancer (mRCC)

ASCO GU 2023: Overall Survival and Efficacy Results of Second-Line Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated in the Randomized Phase II BIONIKK Trial

ASCO GU 2023: A Phase II Trial of Combination of PD-1 Immune Checkpoint Inhibition with All-Lesion Stereotactic Radiation in Oligometastatic Renal Cell Carcinoma

ASCO GU 2023: Treatment-Free Survival Outcomes from the Phase II Study of Nivolumab and Salvage Nivolumab + Ipilimumab in Advanced Clear Cell Renal Cell Carcinoma

ASCO GU 2023: Adjuvant Pembrolizumab for Renal Cell Carcinoma (RCC) Across UCLA Integrated Staging System Risk Groups and Disease Stage: Subgroup Analysis from the KEYNOTE-564 Study

ASCO GU 2023: Treatment-Free Survival Outcomes from the Phase II Study of Nivolumab and Salvage Nivolumab + Ipilimumab in Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)

ASCO GU 2023: Accuracy of Fully Automated, AI-Generated Models Compared with Validated Clinical Model to Predict Post-Operative Glomerular Filtration Rate After Renal Surgery

ASCO GU 2023: Burden of Surgeries and Surgical Complications in Patients with Von Hippel Lindau (VHL) Disease Before and After Treatment with Belzutifan

ASCO GU 2023: C-Reactive Protein as a Predictive Marker for Outcomes with Avelumab + Axitinib in Patients with Poor-Risk Advanced Renal Cell Carcinoma: Exploratory Analysis from JAVELIN Renal 101

ASCO GU 2023: CaboPoint: Interim Results from a Phase 2 Study of Cabozantinib After Checkpoint Inhibitor Therapy in Patients with Advanced Renal Cell Carcinoma

ASCO GU 2023: Outcomes by IMDC Risk in the COSMIC-313 Phase 3 Trial Evaluating Cabozantinib plus Nivolumab and Ipilimumab in First-Line Advanced RCC of IMDC Intermediate or Poor Risk

ASCO GU 2023: Cabozantinib in Combination with Atezolizumab in Non-Clear Cell Renal Cell Carcinoma: Extended Follow-up Results of Cohort 10 of the COSMIC-021 Study

ASCO GU 2023: STARLITE 2: Phase 2 Study of Nivolumab plus 177lutetium-Labeled Anti–carbonic Anhydrase IX (CAIX) Monoclonal Antibody Girentuximab (177Lu-Girentuximab) in Patients with Advanced Clear Cell Renal Cell Carcinoma

ASCO GU 2023: Cabozantinib + Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort

ASCO GU 2023: Radical Nephrectomy in Medically Underserved Patients: Selection Bias and Disparity in Surgical Health Care Delivery

ASCO GU 2023: STARLITE 1: Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment Naïve Patients with Advanced Clear Cell RCC

1
2